Mechanisms of Jisheng-Wumei tablet in laryngeal cancer treatment: a network pharmacology analysis of baicalein's targeting of cytochrome C for laryngeal cancer inhibition
- PMID: 40481938
- PMCID: PMC12145384
- DOI: 10.1007/s12672-025-02829-0
Mechanisms of Jisheng-Wumei tablet in laryngeal cancer treatment: a network pharmacology analysis of baicalein's targeting of cytochrome C for laryngeal cancer inhibition
Abstract
Objectives: Jisheng-Wumei Tablet (JSWMT) is traditionally used in Chinese medicine for cancer therapy and shows potential efficacy against laryngeal cancer. This study aimed to elucidate the active components of JSWMT, with a specific focus on the role of baicalein in targeting cytochrome C (CYCS) to inhibit laryngeal cancer.
Methods: Utilizing network pharmacology, we identified the active ingredients of JSWMT and their corresponding drug targets by leveraging data from the TCMSP and GeneCards databases to pinpoint laryngeal cancer-related targets. Key targets were identified through survival analysis of TCGA expression data, and molecular docking was employed to evaluate the binding affinity between JSWMT compounds and these targets.
Results: Our research identified 35 effective JSWMT ingredients that interact with 132 drug targets, which intersect with 421 targets related to laryngeal cancer. Survival analysis highlighted IL2, CYCS, and CTNNB1 as critical targets significantly correlated with patient survival. Molecular docking demonstrated a strong affinity between CYCS and baicalein, indicating that baicalein is JSWMT's principal active component against laryngeal cancer.
Conclusion: Baicalein is identified as the key active ingredient in JSWMT, targeting CYCS to inhibit the growth of laryngeal cancer cells. This investigation highlights baicalein's potential mechanism of action and underscores the importance of integrating traditional Chinese medicine with contemporary cancer treatment strategies, offering a novel approach to laryngeal cancer therapy.
Keywords: Baicalin; Curcuma zedoary; Cytochrome C; Dark plums; Effective active ingredient; Jisheng-Wumei Tablet (JSWMT); Laryngeal cancer; Network pharmacology; Safflower; Zombie silkworm.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.
Figures





References
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. - PubMed
-
- Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6. - PubMed
-
- Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34. - PubMed
-
- Wang Y, Zhang Q, Chen Y, Liang CL, Liu H, Qiu F, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother. 2020;121: 109570. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous